TLP
ALGS icon

Tri Locum Partners’s Aligos Therapeutics ALGS Stock Holding History

Tri Locum Partners’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,172
Closed -$35K – 44
2022
Q2 		$35K Buy
+1,172
New +$39.8K 0.01% 47

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tri Locum Partners's ALGS Position: Q3 2022 in Review

Tri Locum Partners sold out of Aligos Therapeutics (ALGS) in Q3 2022, closing a stake of 1,172 shares — an estimated $35K sold.

Tri Locum Partners first reported a position in ALGS in Q2 2022 and held it in 1 quarter. The position peaked at $35K in Q2 2022. 52 funds tracked by Wall St. Rank hold ALGS as of Q3 2022.

  • Tri Locum Partners reported no remaining Aligos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Tri Locum Partners sold 1,172 Aligos Therapeutics shares in Q3 2022, an estimated $35K.
  • Tri Locum Partners first reported a position in Aligos Therapeutics in Q2 2022 and held it in 1 quarter.
  • Tri Locum Partners's Aligos Therapeutics position peaked at $35K in Q2 2022.
  • 52 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2022.

Based on Tri Locum Partners's 13F filing for Q3 2022, filed 14 Nov 2022.